Lucitanib
Lucitanib (E-3810) is a potent and selective small molecule inhibitor targeting vascular endothelial growth factor receptors (VEGFR1/2/3) and fibroblast growth factor receptors (FGFR1/2) . It has demonstrated anti-angiogenic and anti-tumor activity in preclinical studies, supporting its investigation in oncology research, particularly for cancers driven by these signaling pathways.
Product Specifications
CAS Number
1058137-23-7
Product Name Alternative
E3810, E-3810, E 3810, Lucitanib, inhibit, Inhibitor, FGFR, FGFR2, FGFR1, Fibroblast growth factor receptor, Vascular endothelial growth factor receptor, VEGFR3, VEGFR, VEGFR1, VEGFR2
Field of Research
Cardiovascular Research, Signal Transduction
Purity
95.68% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.51 mM) ; DMSO:25 mg/mL (56.37 mM)
Smiles
CNC (=O) c1cccc2cc (Oc3ccnc4cc (OCC5 (N) CC5) c (OC) cc34) ccc12
Molecular Formula
C26H25N3O4
Molecular Weight
443.49
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
038429-HRP 200 µL
MID2, CT (MID2, FXY2, RNF60, TRIM1, Probable E3 ubiquitin-protein ligase MID2, Midin-2, Midline defect 2, Midline-2, RING finger protein 60, Tripartite motif-containing protein 1) (Azide free) (HRP) discontinued
Sign In for Pricing
View Details